IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of ...

Dr. Mizui is Founder and President of Eisai Innovations, Inc. and Former Global Business Development and Strategy Head in ...

AstraZeneca’s Phase 3 study in bladder cancer, showed that giving Imfinzi — before and after surgery — cut the risk of death.

GE HealthCare’s recently acquired MIM Software division has secured an FDA clearance for a tool to help quantify the density ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Lenvatinib mesylate is under clinical development by Eisai and currently in Phase II for Acral Lentiginous Melanoma.

Foscenvivint is under clinical development by Eisai and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I drugs for Prostate Cancer have a 76% phase transition success rate ...

Created Through Collaborative Research Between Eisai and PRISM TOKYO, Sept. 8, 2024 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company ...

Leqembi’s rollout has been slowed by bottlenecks related to reimbursement uncertainties, diagnostic test requirements and ...

PRISM BioLab is a discovery and development biotechnology company utilizing proprietary ... PepMetics® targeting CBP/beta-catenin PPIs licensed to Eisai Co., Ltd. and Ohara Pharmaceuticals ...

Although Eisai's target for global Leqembi sales is an ambitious ¥56.5 billion for FY3/25, UBS forecasts sales to reach ¥59 billion, exceeding the company's goal. This projection has been revised ...

Biogen's Leqembi offers hope for Alzheimer's patients by slowing cognitive decline. Patients like Missie Meeks highlight the ...